RecruitingPhase 2NCT05291676

Systems Investigation of Vaccine Responses in Aging and Frailty

Sponsor

Yale University

Enrollment

96 participants

Start Date

Nov 6, 2023

Study Type

INTERVENTIONAL

Conditions

Influenza

Summary

This study will compare the immune response signatures (including immunologic, transcriptomic and metabolomic) of the two influenza vaccines approved for use in adults age 65 and over (Fluad and Fluzone High-Dose).

Eligibility

Min Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Fluad and a biological treatment called Fluzone for people with influenza. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALFluzone

Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer

BIOLOGICALFluad

Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer

Locations(1)

Yale School of Medicine

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05291676

Related Trials

Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

NCT076455341 location

Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies

NCT047721701 location

A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza

NCT07159763181 locations

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

NCT013864241 location

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT071693181 location